Skip to main content

Table 1 Baseline characteristics of the study population

From: Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis

Variables csDMARDs (n=43) TNFi (n=64) P-value
Cardiovascular disease risk factors
 Age, median years (IQR) 58.6 (53.0, 66.0) 58.1 (49.3, 67.0) 0.839
 Female sex 33 (76.7) 54 (84.4) 0.321
 Obesity 5 (11.6) 7 (10.9) 0.999
 Hypertension 19 (44.2) 30 (46.9) 0.784
 Anti-hypertensive drug 17 (39.5) 28 (43.8) 0.784
 Smoking status, ever 18 (42.9) 30 (46.9) 0.684
 Dyslipidaemia 30 (40.2) 34 (59.8) 0.085
 Current statin use 13 (34.2) 10 (15.9) 0.033
 Diabetes mellitus 3 (7.0) 3 (4.7) 0.676
 Anti-diabetic medication 1 (2.3) 1 (1.5) 0.999
 CVD risk factors, median (IQR) 2 (1, 3) 2 (1, 3) 0.199
Rheumatoid arthritis characteristics and treatment
 RF and/or ACPA positive 28 (65.1) 33 (51.6) 0.165
 Disease duration, median years (IQR) 14.1 (11.5) 15.4 (10.5) 0.538
 Methotrexate 38 (88.4) 52 (81.3) 0.192
 Leflunomide 5 (17.9) 12 (19.0) 0.999
 Hydroxychloroquine 9 (31.0) 5 (7.8) 0.009
 Prednisone > 5 mg daily 7 (7.7) 5 (5.5) 0.823
 NSAIDs 6 (20.7) 22 (34.4) 0.227
  1. ACPA, anti-citrullinated peptides antibodies; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitors. All data reported as absolute numbers (percentage) otherwise specified. P-value refers to the chi-squared or Fisher test for categorical variables or independent samples T-test for continuous variables